Suzhou Basecare Medical (HKG:2170) forecasts revenue to increase between 42% to 47% to between 295 million yuan and 305 million yuan in 2024 from 208 million yuan in 2023, according to a Monday filing with the Hong Kong Exchange.
The foreseen rise in revenue is attributable to higher sales following the purchase of BMX Holdco, as well as other sales and purchase agreements for reproductive health products, the filing said.